Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NG-350A |
| Synonyms | |
| Therapy Description |
NG-350A is an oncolytic adenovirus vector expressing a CD40 monoclonal antibody that activates the immune system for an anti-tumor response (PMID: 31890734). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NG-350A | NG350A|NG 350A | CD40 Antibody 16 | NG-350A is an oncolytic adenovirus vector expressing a CD40 monoclonal antibody that activates the immune system for an anti-tumor response (PMID: 31890734). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03852511 | Phase I | NG-350A | First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE) | Completed | USA | 0 |